112 results on '"KISH, JONATHAN"'
Search Results
2. Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes
3. Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer
4. Second Line Advanced or Metastatic Non-Small Cell Lung Cancer Treatment Following Chemo-Immunotherapy: A Retrospective Cohort Study
5. Real-World Observational Study of Outcomes for Acute Myeloid Leukemia (AML) in Patients Treated with Glasdegib or Venetoclax in US Community Oncology Practices
6. Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLNFGFR1): A US Real-World Retrospective Cohort Study
7. Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study
8. Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.
9. Real-world erythropoiesis-stimulating agent (ESA) treatment patterns and outcomes among U.S. patients with lower-risk myelodysplastic syndromes (LR-MDS).
10. Monitoring and management of interstitial lung disease/pneumonitis among patients with metastatic breast cancer treated with trastuzumab deruxtecan.
11. Economic and clinical impact of a novel, light-based, at-home antiviral treatment on mild-to-moderate COVID-19
12. US physician perceptions of treatment decision making for advanced renal cell carcinoma.
13. Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma
14. Impact of Augmented Intelligence on Utilization of Palliative Care Services in a Real-World Oncology Setting
15. Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancer
16. Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
17. Lower-Risk Myelodysplastic Syndromes: Erythropoiesis-Stimulating Agent Treatment Approaches and Outcomes in the United States
18. Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure: Real-World Assessment of Spleen, Symptoms, and Hematologic Response
19. Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure
20. Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea
21. 562 Real-world assessment of current treatment patterns and clinical outcomes among patients with EGFR and ALK wild type non-small cell lung cancer (NSCLC) in the US
22. Harmonic analysis on the positive rationals: computation of character sums
23. Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA
24. Racial disparity in uterine cancer treatment and survival: A matter of Black women’s lives.
25. Real-world clinical effectiveness of eribulin in metastatic breast cancer patients with visceral metastases in the United States.
26. Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States
27. Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States
28. EPR21-037: Prevalence of Low HER2 Expression Among HER2 Negative Metastatic Breast Cancer Patients in U.S: Multi-Site, Retrospective Chart Review Study
29. Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials
30. Abstract PS13-37: Effectiveness of eribulin in poor prognosis subgroups of metastatic breast cancer (mBC) patients (elderly, African Americans, and patients with liver metastases) in the United States
31. Abstract PS7-55: Evolution of prescribing trends for HR+/HER2- metastatic breast cancer (mBC) in a post-CDK4/6i world
32. Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States
33. Real-World Investigation of Spleen, Symptom, and Hematologic Response in Patients with Myelofibrosis Treated with First-Line Ruxolitinib
34. Physician treatment of metastatic triple-negative breast cancer in the immuno-oncology era: a discrete choice experiment
35. 731 Costs of care for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): a real-world claims analysis
36. Real-world utilization of quality-of-life data: Perspectives from community oncology providers.
37. Linking reimbursement to patient-reported quality of life: Provider perspectives.
38. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs
39. Naturally Occurring Water Pollutants
40. MPN-067: Ruxolitinib Retreatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
41. MPN-070: Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who are Resistant to or Intolerant of Hydroxyurea
42. Care Coordination Between Prescribers and the Specialty Pharmacy for Multiple Myeloma: Qualitative Insights Into Designing a Quality Improvement Program for Multisite Community Oncology Practices
43. Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma
44. Impact of augmented intelligence (AI) on identification and management of depression in oncology.
45. Real-world disease burden for patients (pts) with myelofibrosis (MF) treated with ruxolitinib (RUX).
46. Prescribing preferences for hormone sensitive (HR+) metastatic breast cancer (mBC) in the CDK 4/6 inhibitor (CDK 4/6i) era.
47. Real-world outcomes of pembrolizumab plus carboplatin plus paclitaxel or nab-paclitaxel in non-small cell lung cancer (NSCLC).
48. Gender-based disparities in clinical trials supporting FDA approval of oncology drugs.
49. Physician treatment preferences for metastatic triple negative breast cancer (mTNBC) in an era of immunotherapy.
50. Impact of augmented intelligence (AI) on utilization of palliative care (PC) services in oncology.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.